BCDA Stock Overview
A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
BioCardia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.26 |
| 52 Week High | US$10.95 |
| 52 Week Low | US$1.84 |
| Beta | 1.27 |
| 11 Month Change | -8.87% |
| 3 Month Change | -9.24% |
| 1 Year Change | -78.76% |
| 33 Year Change | -93.15% |
| 5 Year Change | -96.72% |
| Change since IPO | -98.89% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
May 14
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12BioCardia stock rises on contract for delivery products for BlueRock's cell therapies
Aug 24Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Aug 24Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
May 10We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Jan 06We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Sep 23Shareholder Returns
| BCDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.2% | -3.7% | 0.3% |
| 1Y | -78.8% | 15.2% | 31.1% |
Return vs Industry: BCDA underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: BCDA underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| BCDA volatility | |
|---|---|
| BCDA Average Weekly Movement | 27.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCDA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCDA's weekly volatility has increased from 18% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
BioCardia, Inc. Fundamentals Summary
| BCDA fundamental statistics | |
|---|---|
| Market cap | US$7.48m |
| Earnings (TTM) | -US$7.72m |
| Revenue (TTM) | US$71.00k |
111.5x
P/S Ratio-1.0x
P/E RatioIs BCDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCDA income statement (TTM) | |
|---|---|
| Revenue | US$71.00k |
| Cost of Revenue | US$7.73m |
| Gross Profit | -US$7.65m |
| Other Expenses | US$67.00k |
| Earnings | -US$7.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | -10,781.69% |
| Net Profit Margin | -10,876.06% |
| Debt/Equity Ratio | 0% |
How did BCDA perform over the long term?
See historical performance and comparison